SCHEMBL3153755

SCHEMBL3153755

Fc1ccc2ccccc2c1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
HSD17B10 Q99714 2/20 0.46
CYP2A6 P11509 1/20 0.46
TSHR P16473 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
HPRT1 P00492 2/20 0.45
WDR5 P61964 1/20 0.44
CES1 P23141 1/20 0.42
MAPT P10636 2/20 0.41
ESR1 P03372 2/20 0.40
ESR2 Q92731 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
CYP1B1 Q16678 2/20 0.39
HIF1A Q16665 1/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18165257 0.89 ALDH1A1 (0.44) ALDH1A1HSD17B10CYP2A6TSHRTDP1
SCHEMBL7783885 0.84 CES1 (0.41) ALDH1A1HSD17B10CYP2A6TSHRTDP1
SCHEMBL29213863 0.84 ESR1 (0.46) ALDH1A1HSD17B10CYP2A6TSHRTDP1
SCHEMBL28596672 0.84 DNMT1 (0.42) ALDH1A1HSD17B10CYP2A6TSHRTDP1
SCHEMBL7033272 0.80 TRPV6 (0.39) ALDH1A1HSD17B10CYP2A6TSHRTDP1
SCHEMBL7719797 0.77 DNMT1 (0.46) ALDH1A1HSD17B10CYP2A6TSHRTDP1
SCHEMBL22005379 0.76 HPRT1 (0.34) ALDH1A1HSD17B10CYP2A6TSHRTDP1
SCHEMBL28896074 0.76 ALDH1A1 (0.48) ALDH1A1HSD17B10CYP2A6TSHRTDP1
SCHEMBL191449 0.76 DNMT1 (0.48) ALDH1A1HSD17B10CYP2A6TSHRTDP1
SCHEMBL30034855 0.76 DNMT1 (0.48) ALDH1A1HSD17B10CYP2A6TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240251665-A1 TRANSVERSE CURRENT SUPPRESSING MATERIAL, CARBAZOLE COMPOUND, HOLE-INJECTION LAYER AND ORGANIC ELECTROLUMINESCENT ELEMENT TOSOH CORPORATION (JP) 2024-07-25 US disclosed
CN-117044428-A Lateral current suppressing material, carbazole compound, hole injection layer, and organic electroluminescent element 东曹株式会社 2023-11-10 CN disclosed
US-11638713-B2 Patentiflorin A analogs as antiviral agents HONG KONG BAPTIST UNIVERSITY (CN) 2023-05-02 US disclosed
WO-2022211123-A1 TRANSVERSE CURRENT SUPPRESSING MATERIAL, CARBAZOLE COMPOUND, HOLE INJECTION LAYER, AND ORGANIC ELECTROLUMINESCENT ELEMENT 東ソー株式会社 2022-10-06 WO disclosed
US-20210060042-A1 Patentiflorin A Analogs as Antiviral Agents HONG KONG BAPTIST UNIVERSITY (HK) 2021-03-04 US disclosed
CN-109311844-A Triaizine compounds, its manufacturing method and the organic electroluminescent device as constituent 东曹株式会社 2019-02-05 CN disclosed
EP-1452514-B1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK & CHEMICALS (JP) 2010-03-31 EP disclosed
EP-0952135-B1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK & CHEMICALS (JP) 2005-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11638713-B2 Patentiflorin A analogs as antiviral agents MAVS, MIF, SARS1 ALDH1A1 2987/4885HSD17B10 4179/4885CYP2A6 1457/4885
US-20240251665-A1 TRANSVERSE CURRENT SUPPRESSING MATERIAL, CARBAZOLE COMPOUND, HOLE-INJECTION LAYER AND ORGANIC ELECTROLUMINESCENT ELEMENT AXIN2, FZD7, SLC39A3 ALDH1A1 3265/4885HSD17B10 3174/4885CYP2A6 2185/4885
US-20210060042-A1 Patentiflorin A Analogs as Antiviral Agents MAVS, MIF, SARS1 ALDH1A1 2987/4885HSD17B10 4179/4885CYP2A6 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.